A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Summary

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.

Conditions

• Cancer

Interventions

DRUG

Atezolizumab

Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).

DRUG

Bevacizumab

Bevacizumab will be administered as directed per the parent study.

DRUG

Alectinib

Alectinib will be administered as directed per the parent study.

DRUG

Cobimetinib

Cobimetinib will be administered as directed per the parent study.

DRUG

Vemurafenib

Vemurafenib will be administered as directed per the parent study.

DRUG

FAP IL2V

FAP IL2V will be administered as directed per the parent study.

DRUG

Venetoclax

Venetoclax will be administered as directed per the parent study.

DRUG

Enzalutamide

Enzalutamide will be administered as directed per the parent study.

DRUG

Pembrolizumab

Pembrolizumab will be administered as directed per the parent study.

DRUG

Sunitinib

Sunitinib will be administered as directed per the parent study.

DRUG

Niraparib

Niraparib will be administered as directed per the parent study.

DRUG

Cabozantinib

Cabozantinib will be administered as directed per the parent study.

DRUG

Pemetrexed

Pemetrexed will be administered as directed per the parent study.

DRUG

Paclitaxel

Paclitaxel will be administered as directed per the parent study.

DRUG

Emactuzumab

Emactuzumab will be administered as directed per the parent study.

DRUG

Rucaparib

Rucaparib will be administered as directed per the parent study.

Sponsors & Collaborators

• Hoffmann-La Roche

  lead INDUSTRY

Principal Investigators

• Clinical Trials · Hoffmann-La Roche

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-02-28

Primary Completion

2028-07-05

Completion

2028-07-05

FDA Drug

Yes

Countries

• United States
• Australia
• Belgium
• Brazil
• Bulgaria
• Chile
• Czechia
• Denmark
• France
• Germany
• Greece
• Guatemala
• Hong Kong
• Hungary
• Italy
• Japan
• Mexico
• Poland
• Romania
• Russia
• South Korea
• Spain
• Thailand
• Ukraine

Study Locations